Contemporary intravesical treatment options for urothelial carcinoma of the bladder

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 10, 2006, Pages 1027-1036

  Brassell, Stephen A ^a   Kamat, Ashish M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

BCG; Bladder cancer; Intravesical therapy; Transitional cell carcinoma

Indexed keywords

ALPHA2B INTERFERON; ANTHRACYCLINE; BACTERIAL DNA; BCG VACCINE; BETA INTERFERON; BROPIRIMINE; DESMOPRESSIN; DOXORUBICIN; EPIRUBICIN; FLAVOPIRIDOL; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MITOMYCIN C; PSEUDOMONAS EXOTOXIN; RUBRATIN; SURAMIN; THIOTEPA; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; VALRUBICIN; VERAPAMIL; VISCUM ALBUM LECTIN;

ABSENCE OF SIDE EFFECTS; ARTICLE; BLADDER CARCINOMA; BLADDER IRRITATION; CANCER GROWTH; CANCER RECURRENCE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG POTENTIATION; DYSURIA; ELECTROSTIMULATION THERAPY; FEVER; HUMAN; HYPERTHERMIC THERAPY; LEUKOPENIA; MAINTENANCE THERAPY; MALAISE; MEDICAL LITERATURE; NAUSEA; NONHUMAN; PERIOPERATIVE PERIOD; POLLAKISURIA; TRANSURETHRAL RESECTION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 33751577202     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0086     Document Type: Article

References (90)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-1086.
3. Lamm DL, Herr H, Jakse G, et al. Updated concepts and treatment of carcinoma in situ. Urol Oncol 1998;4:130-135.
4. Abel PD. Follow-up of patients with "superficial" transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol 1993;72:135-142.
5. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000;163:1124-1129.
6. Pearl R. Cancer and tuberculosis. Proc Natl Acad Sci U S A 1929;9:97.
7. Morales A, Eidenger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial tumors. J Urol 1976;116:180-183.
8. Ludwig AT, Moore JM, Luo Y, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette-Guerin- induced antitumor activity. Cancer Res 2004;64:3386-3390.
9. Lamm DL, Thor DE, Harris SC, et al. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 1980;124:38-40.
10. Herr HW. Transurethral resection and intravesical therapy of superficial bladder tumors. Urol Clin North Am 1991;18:525-528.
11. Pagano F, Bassi P, Milani C, et al. Low dose BCG regimen in superficial bladder cancer therapy: is it effective? J Urol 1991;146:32-35.
12. Melekos MD, Chionis H, Pantazakos A, et al. Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J Urol 1993;149:744-748.
13. Krege S, Giani G, Meyer R, et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J Urol 1996;156:962-966.
14. Dalbagni G, Herr HW. Superficial bladder cancer: new strategies in diagnosis and treatment. Urol Clin North Am 2000;27:137-146.
15. Herr HW, Pinsky CM, Whitmore WF Jr, et al. Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology 1985;25:119-123.
16. Herr HW, Laudone VP, Badalament RA, et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988;6:1450-1455.
17. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-1970.
18. Coplen DE, Marcus MD, Myers JA, et al. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol 1990;144:652-657.
19. Shapiro A, Vakar F, Kamat AM. Diffuse granulomatous mesenteric disease caused by intravesical bacillus Calmette-Guérin instillation masquerading as peritoneal carcinomatosis. Urol Oncol 2005;23:352-353.
20. Corti OD, Rivera GP, Aviles JJ, et al. Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG: comparison with other doses. Actas Urol Esp 1993;17:239-242.
21. Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174(4 Pt 1):1242-1247.
22. Sylvester RJ, van der Meijden AP, Witjes JA, et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86-91.
23. Palou J, Laguna P, Millán-Rodríguez F, et al. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 2001;165:1488-1491.
24. Nadler RB, Catalona WJ, Hudson MA, et al. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 1994;152(2 Pt 1):367-373.
25. Badalament RA, Herr HW, Wong GY. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol 1987;5:441-449.
26. Hudson MA, Ratliff TL, Gillen DP. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 1987;138:295-298.
27. Bartoletti R, Massimini G, Criscuolo D, et al. Interferon alpha 2a in superficial bladder cancer prophylaxis: toleration and long-term follow-up. A phase I-II study. Anticancer Res 1991;11:2167-2170.
28. Portillo J, Martin B, Hernandez R, et al. Results at 43 months follow up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology 1997;49:187-190.
29. Torti FM, Shortliffe LD, Williams RD, et al. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group study. J Clin Oncol 1988;6:476-483.
30. Glashan RW. A randomized controlled study of intravesical alpha-2b interferon in carcinoma in situ of the bladder. J Urol 1990;144:658-661.
31. Engelmann U, Knopf HJ, Graff J. Interferon-alpha 2b installation prophylaxis in superficial bladder cancer - a prospective, controlled three-armed trial: Project Group Bochum - interferon and superficial bladder cancer. Anticancer Drugs 1992;3:33-37.
32. Raitanen MP, Lukkarinen O. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder: Finnish Multicentre Study Group. Br J Urol 1995;76:697-701.
33. Jimenez-Cruz JT, Vera-Donoso CD, Leiva O, et al. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): multicenter trial comparing bacillus Calmette-Guerin and interferon-alpha. Urology 1997;50:529-535.
34. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon alpha-2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001;166:1300-1304.
35. Punnen SP, Chin JL, Jewett MA. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer with intravesical BCG and interferon combination therapy. Can J Urol 2003;10:1790-1795.
36. Luciani LG, Neulander E, Murphy WM, et al. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology 2001;58:376-379.
37. O'Donnell MA, Lilli K, Leopold C. National Bacillus Calmette-Guerin/ Interferon Phase 2 Investigator Group: interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004;172:888-893.
38. Jurincic CD, Engelmann U, Gasch J, et al. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol 1988;139:723-726.
39. Kalble T, Mohring K, Ikinger U, et al. Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study. Urologe A 1991;30:118-121.
40. Witjes WP, Konig M, Boeminghaus FP, et al. Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naïve patients with carcinoma in situ of the urinary bladder: European Bropirimine Study Group. Eur Urol 1999;36:576-581.
41. Sarosdy MF, Tangen CM, Weiss GR, et al. A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. Urol Oncol 2005;23:386-389.
42. Grasso M, Torelli F, Scannapieco G. Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2. J Immunother 2001;24:184-187.
43. Clinton SK, Canto E, O'Donnell MA. Interleukin-12. Opportunities for the treatment of bladder cancer. Urol Clin North Am 2000;27:147-155.
44. Weiss GR, O'Donnell MA, Loughlin K, et al. Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother 2003;26:343-348.
45. Glazier DB, Bahnson RR, McLeod DG, et al. Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. J Urol 1995;154:66-68.
46. Stravoravdi P, Toliou T, Kirtsis P, et al. A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa. J Interferon Cytokine Res 1999;19:221-225.
47. Filion MC, Phillips NC. Therapeutic potential of mycobacterial cell wall-DNA complexes. Expert Opin Investig Drugs 2001;10:2157-2165.
48. Morales A, Chin JL, Ramsey EW. Mycobacterial cell wall extract for the treatment of carcinoma in situ of the bladder. J Urol 2001;166:1633-1637.
49. Zlotta AR, Schulman CC. Biological response modifiers for the treatment of superficial bladder tumors. Eur Urol 2000;37:10-15.
50. Elsässer-Beile U, Leiber C, Wolf P, et al. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract. J Urol 2005;174:76-79.
51. Yan X, Ding Q, Zhang YF, Xu YH. Inhibitory effect of recombinant transforming growth factor alpha-pseudomonas exotoxin 40 on human bladder cancer cell proliferation. Zhonghua Wai Ke Za Zhi 2004;42:1457-1459.
52. Messing EM, Catalona W. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughan EDJr, et al., eds. Campbell's Urology, 7th ed. Philadelphia: WB Saunders, 1998:2327-2410.
53. Mostafid AH, Rajkumar RG, Stewart AB, Singh R. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. BJU Int 2006;97:509-512.
54. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996;155:1233-1238.
55. Conrad S, Friedrich MO, Schwaibold H, et al. Long-term prophylaxis with mitomycin C (MMC) further reduces tumor recurrence compared to short-term prophylaxis with MMC or bacillus Calmette-Guerin (BCG). J Urol 2004;171:71A.
56. Kurth KH, Bouffioux C, Sylvester R, et al. Treatment of superficial bladder tumors: achievement and needs. Eur Urol 2000;37[Suppl 3]:1-9.
57. Bohle A, Jocham D, Bock PR. Intravesical BCG versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-95.
58. Bohle A, Bock PR. Intravesical BCG versus mitomycin C in superficial cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-686.
59. Sylvesteer RJ, Adrian PM, van der Meijden J, et al. BCG versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;175:86-92.
60. Huncharek M, Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 2004;27:522-528.
61. Duque JL, Loughlin KR. Superficial bladder cancer: new strategies in diagnosis and treatment. Urol Clin North Am 2000;27:125-135.
62. Au JL, Badalament RA, Wientjes G, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomised phase III trial. J Natl Cancer Inst 2001;93:597-604.
63. Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomised study. J Urol 2003;170:777-782.
64. Gofrit ON, Shapiro A, Pode D. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high grade superficial bladder cancer. Urology 2004;63:466-471.
65. Rintala E, Jauhiainen K, Rajala P, et al. Alternating mitomycin-C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. J Urol 1995;154:2050-2053.
66. Rintala E, Jauhiainen K, Kaasinen E, et al. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J Urol 1996;156:56-59.
67. Witjes JA, Caris CT, Mungan NA, et al. Results of a randomised phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol 1998;160:1668-1671.
68. Kaasinen E, Wijkstrom H, Malmstrom PU, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol 2003;43:637-645.
69. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006;7:43-51.
70. Kaasinen E, Rintala E, Hellstrom P, et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002;42:167-174.
71. Xin Y, Lyness G, Chen D. Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C. J Urol 2005;174:322-327.
72. Bouffioux C, Kurth KH, Bono A, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995;153:934-941.
73. Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002;20:3193-3198.
74. Dalbagni G, Mazumdar M, Russo P, et al. Phase II trial of intravesical gemcitabine in BCG-refractory transitional cell carcinoma of the bladder [abstract]. J Urol 2004;171:Abstract 274A.
75. O'Donnell MA. Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am 2005;32:121-131.
76. Ali-el-Dein B, el-Baz M, Aly AN, et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol 1997;158:68-73.
77. Kurth K, Tunn U, Ay R, et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a EORTC randomized trial comparing doxorubicin, ethoglucid, and TUR alone. J Urol 1997;158:378-384.
78. Oosterlinck W, Kurth KH, Schroder F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single state Ta, T1 papillary carcinoma of the bladder. J Urol 1993;149:749-752.
79. Rajala P, Kaasinen E, Raitanen M, et al. Perioperative single dose instillation of epirubicin or interferon-α after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study-FinnBladder III long-term results. J Urol 2002;168:981-985.
80. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: the Valrubicin Study Group. J Urol 2000;163:761-767.
81. Isaka S, Okano T, Abe K, et al. Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder cancer. Cancer Chemother Pharmacol 1992;30:41-44.
82. Sekine H, Ohya K, Kojima SI. Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. Int J Urol 2001;8:483-486.
83. Fukui I, Kihara K, Sekine H, et al. Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response. Cancer Chemother Pharmacol 1992;30:37-40.
84. Wirger A, Perabo FG, Burgemeister S, et al. Flavopiridol, an inhibitor of cyclin- dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res 2005;25:4341-4347.
85. Lamm DL, Riggs DR. The potential application of Allium sativum (garlic) for the treatment of bladder cancer. Urol Clin North Am 2000;27:157-162.
86. Hsieh JT, Dinney CP, Chung LW. The potential role of gene therapy in the treatment of bladder cancer. Urol Clin North Am 2000;27:103-113.
87. Benedict WF, Tao Z, Kim CS, et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 2004;10:525-532.
88. Gomella LG, Mastrangelo MJ, McCue PA, et al. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 2001;166:1291-1295.
89. Le Visage C, Rioux-Leclercq N, Haller M, et al. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J Urol 2004;171:1324-1329.
90. Divrik RT, Yildirim U, Zorlu F, The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006;175:1641-1644.